Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Compass Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Compass Therapeutics, Inc.

CMPX

Compass Therapeutics, Inc.

About Compass Therapeutics, Inc.

Compass Therapeutics is a clinical-stage biopharmaceutical company focused on developing antibody-based immuno-oncology therapeutics. Its pipeline includes bispecific antibodies targeting tumor angiogenesis, immune checkpoints, and tumor microenvironment modulation. The company aims to treat various solid tumors by enhancing immune responses and disrupting tumor blood supply, leveraging proprietary technologies for antibody discovery, engineering, and manufacturing.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Compass Therapeutics, Inc.

1
1
Compass Therapeutics, Inc. Compass Therapeutics Reports $18.3 Million Net Loss in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Compass Therapeutics, Inc. Compass Therapeutics Reports $66.5 Million Net Loss and Raises $129.6 Million in Financing

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Compass Therapeutics, Inc. Compass Therapeutics Reports $14.3 Million Net Loss in Q3 2025, Total Assets Rise to $231.3 Million

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Compass Therapeutics, Inc. Compass Therapeutics Reports $19.9 Million Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Compass Therapeutics, Inc. Compass Therapeutics Reports $16.6 Million Net Loss in Q1 2025, Highlights Clinical Progress

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Compass Therapeutics, Inc. Compass Therapeutics Reports $49.4 Million Net Loss for 2024, Licensing Revenue of $850,000

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Compass Therapeutics, Inc. Compass Therapeutics Reports Financial Results for Nine Months Ended September 30, 2024, with Increased Cash and Licensing Revenue

Via official filing (AI summary) | over 1 year ago | 0 comments